The role of immunotherapy and targeted therapy in the multimodal therapy for resectable lung cancer

Keyphrases

• Combined Modality Therapy 100%
• Targeted Therapy 100%
• Resectable Lung Cancer 100%
• Immunotherapy Treatment 100%
• Patient Selection 50%
• Phase I Trial 50%
• Oncogenic Drivers 50%
• Clinical Endpoints 50%
• Perioperative Period 50%
• Immunotherapeutics 50%
• Biomarker Endpoint 50%
• Oncology Care 50%
• Thoracic Oncology 50%

Medicine and Dentistry

• Biological Marker 100%
• Targeted Therapy 100%
• Immunotherapy 100%
• Lung Cancer 100%
• Carcinogenesis 50%
• Clinical Trial 50%
• Patient Selection 50%
• Non Small Cell Lung Cancer 50%
• Perioperative Period 50%
• Thoracic Oncology 50%